An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy

Human Gene Therapy - Tập 30 Số 9 - Trang 1117-1132 - 2019
Yuefeng Yang1,2, Weidong Xu2, Di Peng3, Hao Wang1, Xiaoyan Zhang1, Hua Wang1, Fengjun Xiao1, Yangyong Zhu4,5, Yuan Ji4,5, Kamalakar Gulukota6,4, Donald L. Helseth6,4, Kathy A. Mangold7, Megan Sullivan7, Karen L. Kaul7, Wenge Wang8,4, Bellur S. Prabhakar9, Jinnan Li3, Xuejie Wu3, Lisheng Wang1, Prem Seth2
1Department of Experimental Hematology, Beijing Institute of Radiation Medicine, Beijing, China
2Gene Therapy Program, Department of Medicine, NorthShore Research Institute, an Affiliate of the University of Chicago, Evanston, Illinois
3Department of Urology, The Third Medical Center of Chinese People's Liberation Army, Beijing, China
4NorthShore University HealthSystem, Evanston, Illinois
5Program of Computational Genomics and Medicine, Department of Surgery; NorthShore University HealthSystem, Evanston, Illinois
6Center for Personalized Medicine, Department of Surgery; NorthShore University HealthSystem, Evanston, Illinois
7Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, Illinois
8Biostatistics and Clinical Research Informatics, Department of Surgery; NorthShore University HealthSystem, Evanston, Illinois
9Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, Illinois.

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1001/jamaoncol.2015.1198

Nathan MR, 2017, Breast

10.1016/j.cell.2008.07.001

10.1097/CCO.0b013e32835b6371

10.1101/cshperspect.a022301

10.1016/j.pharmthera.2014.11.001

10.1089/hum.2006.17.1152

10.1089/hum.2010.018

10.1089/hum.2012.040

10.1038/mt.2011.114

10.1016/j.coi.2015.01.006

10.1158/1078-0432.CCR-15-1507

10.1126/science.aan6733

10.1158/1078-0432.CCR-16-2569

10.1158/1078-0432.CCR-15-1315

Cimino-Mathews A, 2015, Oncology (Williston Park), 29, 375

10.1016/j.pharmthera.2015.01.003

10.1016/j.cell.2015.07.061

10.1016/bs.ai.2015.12.003

10.1016/j.coi.2010.11.013

10.1158/2159-8290.CD-16-1223

10.1007/s10555-010-9247-y

10.1016/j.ccr.2005.10.012

10.3109/08977194.2015.1010645

10.1038/nature25492

10.1038/nature25501

10.1038/sj.cgt.7701105

10.1038/cgt.2012.41

Katayose D, 1995, Clin Cancer Res, 1, 889

10.1038/nmeth.2956

10.1093/jnci/djv129

10.1080/01621459.2012.746058

10.1186/s40425-016-0158-5

10.18632/oncotarget.18309

10.1001/jamaoncol.2016.2064

10.1016/j.ymthe.2017.03.026

Asad AS, 2017, Expert Opin Biol Ther, 1

10.1158/1078-0432.CCR-06-1007

10.1016/j.bone.2010.08.004

10.1038/ncb3015

10.1016/j.cell.2011.09.024

10.1016/j.semcancer.2015.08.009

10.1182/blood-2016-01-636399

10.1101/cshperspect.a006486

10.1215/15228517-2007-010

10.3892/or_00001028

10.4049/jimmunol.178.5.2883

10.1146/annurev-immunol-032712-100008

10.1016/j.cytogfr.2013.01.005

10.1073/pnas.1500712112

10.1080/2162402X.2015.1074374

10.1158/1078-0432.CCR-07-1654

10.1007/s10555-010-9226-3

10.1023/A:1022951824806

10.1016/j.immuni.2014.10.017

Herbertz S, 2015, Drug Des Devel Ther, 9, 4479

10.1038/mt.2014.80

10.1038/mt.2011.89

10.1371/journal.pone.0097407

10.18632/oncotarget.5116

10.1038/sj.gt.3300636

10.1200/JCO.2005.03.4116

10.1016/S0003-4975(00)01815-4

10.1016/j.ijrobp.2014.02.034

10.4161/21624011.2014.947872

Thông tin
Thông tin xuất bản

Human Gene Therapy

Tập 30 Số 9

1117-1132

Thông tin tác giả